This is a renewal application for The Pittsburgh Pediatric Rheumatology Training Grant. Pediatric rheumatology focuses on musculoskeletal and autoimmune diseases of childhood. Serving this population of children are 237 board-certified pediatric rheumatologists in the United States (as of 2008). All but a handful of these are clinicians who do not engage in research. As a result, few pediatric rheumatologists have had research mentorship and they lack the skills to perform cutting edge research. The Division of Pediatric Rheumatology at the Children's Hospital of Pittsburgh, with substantial and sustained institutional support, has endeavored to create a national center of excellence offering comprehensive, state-of-the-art clinical care, educational programs, and competitive research involving clinical, translational, and basic sciences. Our Training Program is one of only two NIH-funded training programs dedicated to pediatric rheumatology. One of our central missions is to educate a new generation of academic pediatric rheumatologists who can play a leading role in the specialty as physician scientists. The goal is to provide a prime source of well- trained M.D. academic pediatric rheumatologists and Ph.D. scientists to serve the national need for cutting- edge research in the pediatric rheumatic diseases. To achieve this mission, we seek to provide, within a single center, the research role models, mentorship, and rich environment necessary for nurturing such individuals and ensuring their success. Support is requested to continue the current number of trainees in our program, currently four trainees per year, in order to provide two new trainees per year and two years of support for each trainee. The trainees will consist of two types of individuals. At least 75% will be pediatric rheumatology M.D. fellows who have completed a first year of clinical training. Following a first year of intensive clinical training, they will select a mentor from among the program faculty in order to gain exceptional research experience that will be used as the basis of an independent academic career. Up to 25% will be Ph.D. trainees who desire to focus their research careers in pediatric rheumatology. They will select a mentor from among the faculty who study the pediatric rheumatic diseases.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Program Officer
Wang, Yan Z
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
Schools of Medicine
United States
Zip Code
Ferguson, Ian D; Griffin, Patricia; Michel, Joshua J et al. (2018) T Cell Receptor-Independent, CD31/IL-17A-Driven Inflammatory Axis Shapes Synovitis in Juvenile Idiopathic Arthritis. Front Immunol 9:1802
Campfield, Brian T; Eddens, Taylor; Henkel, Matthew et al. (2017) Follistatin-like protein 1 modulates IL-17 signaling via IL-17RC regulation in stromal cells. Immunol Cell Biol 95:656-665
Ardalan, Kaveh; Zigler, Christina K; Torok, Kathryn S (2017) Predictors of Longitudinal Quality of Life in Juvenile Localized Scleroderma. Arthritis Care Res (Hoboken) 69:1082-1087
Poff, S; Li, S C; Kelsey, C E et al. (2016) Durometry as an outcome measure in juvenile localized scleroderma. Br J Dermatol 174:228-30
Way, Emily E; Trevejo-Nunez, Giraldina; Kane, Lawrence P et al. (2016) Dose-Dependent Suppression of Cytokine production from T cells by a Novel Phosphoinositide 3-Kinase Delta Inhibitor. Sci Rep 6:30384
Niehaus, Jason Z; Good, Misty; Jackson, Laura E et al. (2015) Human SERPINB12 Is an Abundant Intracellular Serpin Expressed in Most Surface and Glandular Epithelia. J Histochem Cytochem 63:854-65
Niehaus, Jason Z; Miedel, Mark T; Good, Misty et al. (2015) SERPINB12 Is a Slow-Binding Inhibitor of Granzyme A and Hepsin. Biochemistry 54:6756-9
Ferguson, Ian D; Weiser, Peter; Torok, Kathryn S (2015) A Case Report of Successful Treatment of Recalcitrant Childhood Localized Scleroderma with Infliximab and Leflunomide. Open Rheumatol J 9:30-5
Aggarwal, Rohit; Cassidy, Elaine; Fertig, Noreen et al. (2014) Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 73:227-32
Campfield, Brian T; Nolder, Christi L; Marinov, Anthony et al. (2014) Follistatin-like protein 1 is a critical mediator of experimental Lyme arthritis and the humoral response to Borrelia burgdorferi infection. Microb Pathog 73:70-9

Showing the most recent 10 out of 28 publications